Sam Altman, the chief executive of OpenAI, recently invested US$180 million into Retro Biosciences—a company seeking to extend human lifespans by ten healthy years.
The rich are pouring millions into life extension research, but does it have any ethical value?
Reader’s Picks
-
Social service systems struggle to successfully engage with men as parents. A new book co-authored and co-edited by Georgia State [...]
-
Sperm and egg donors who assumed they would remain anonymous have been tracked down by their children using DNA tests, [...]
-
Black and Asian people with darker skin shades can be the subject of prejudice and insults from lighter skin members [...]